Valued at USD 38.88 billion in 2025, the non-small cell lung cancer market is projected to reach USD 42.64 billion in 2026 and USD 129.88 billion by 2034, growing at a CAGR of 14.3% during the forecast period 2026–2034. Expansion is propelled by a fast-changing treatment landscape in which targeted therapy and immunotherapy are improving survival outcomes in advanced and metastatic disease. Key players include Roche Holding AG, AstraZeneca PLC, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Eli Lilly and Company, Novartis AG, Johnson & Johnson, Amgen Inc., BeiGene Ltd., Exelixis Inc., and Mirati Therapeutics Inc.

Targeted Therapy Anchors Treatment Choice

The targeted therapy segment dominated the non-small cell lung cancer market by treatment in 2025, supported by known driver mutations such as EGFR, ALK and ROS1. Novel tyrosine kinase inhibitors and resistance-specific treatments are enhancing progression-free survival in advanced-stage patients, while collaborations between diagnostics and pharmaceutical companies are improving drug accessibility. Recent approvals show the momentum. In June 2025, AstraZeneca's DatroWay received U.S. FDA approval for EGFR exon 20 insertion-mutated NSCLC, and in May 2025 the FDA approved AbbVie's EMRELIS for previously treated advanced NSCLC with high c-Met protein overexpression. In October 2024, Enhertu became the first HER2-directed therapy approved in China for HER2-mutant metastatic NSCLC.

Immunotherapy and Immune Checkpoint Inhibitors Gain Ground

The immunotherapy segment is expected to grow at the highest CAGR of 13.24% during the forecast period, owing to its ability to significantly extend survival in advanced-stage NSCLC patients. The rising approval and expansion of immune checkpoint inhibitors targeting PD-1 and PD-L1 have transformed the treatment landscape, while increasing biomarker testing enables precise patient stratification. Ongoing trials of combination regimens are extending immunotherapy across multiple treatment lines. In May 2026, BioNTech and Bristol Myers Squibb initiated five additional pivotal trials for pumitamig, a PD-L1/VEGF-A bispecific antibody, as part of a broader solid tumor strategy. In Europe, Novocure's Optune Lua received CE Mark approval in April 2025 for metastatic NSCLC in combination with immune checkpoint inhibitors.

Read More @ https://www.polarismarketresearch.com/industry-analysis/non-small-cell-lung-cancer-market

Hospital Pharmacy Leads While Online Pharmacy Accelerates

The hospital pharmacy segment accounted for the largest distribution share of 66.89% in 2025, owing to its role in administering complex treatments such as immunotherapy and combination regimens. Most targeted and biologic therapies require physician oversight and infusion facilities, and hospitals are better equipped for pharmacovigilance and adverse event monitoring. By contrast, the online pharmacy segment is projected to grow at the fastest pace, supported by improving digital health access, e-pharmacy expansion and patient preference for home delivery. Telemedicine and e-prescriptions are streamlining oncology drug purchases for patients in remote or underserved regions, and competitive pricing and adherence-support programs make online pharmacy a viable channel for chronic NSCLC treatment management.

Regional Momentum and Future Outlook

North America held a 44.55% share in 2025, with the U.S. dominating the regional landscape through widespread molecular testing and early adoption of FDA-approved therapies. Asia Pacific is projected to grow at the fastest CAGR of 14.3%, with China supported by the Healthy China 2030 initiative and the inclusion of innovative drugs in the National Reimbursement Drug List. Europe is expected to hold a substantial share in 2034 as public insurance schemes adopt immuno-oncology drugs. Rising investment in clinical trials and improved health infrastructure position targeted therapy and immunotherapy for sustained expansion across the forecast period.

More Trending Latest Reports By Polaris Market Research:

medical-devices-market

natural-disaster-management-market

petrochemicals-market

autonomous-mobile-robot-market

intraocular-lens-market

us-industrial-fans-market

benchmarking-performance-top-5-companies-in-air-purifiers

fishing-apparel-and-equipment-market

waterproofing-membranes-market